FIELD: pharmaceuticals.
SUBSTANCE: invention relates to the pharmaceutical industry and is a composition effective to enhance energy metabolism comprising at least 0.05 mg of a phosphodiesterase 5 (PDE 5) inhibitor and at least 500 mg leucine and/or at least 200 mg leucine metabolite, wherein the PDE 5 inhibitor contains sildenafil and wherein said leucine metabolite is selected from the group consisting of beta-hydroxymethyl butyrate (HMB), keto-isocaproic acid (KIC), and α-hydroxyisocaproic acid.
EFFECT: invention provides effective enhancement of regulation of energy metabolism, consisting in a synergistic increase in the oxidation of fatty acids in adipocytes and the utilisation of glucose.
24 cl, 27 dwg, 10 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR METABOLIC PATHWAY MODULATION | 2012 |
|
RU2631597C2 |
| TREATMENT OF LIVER, BILE DUCT AND PANCREATIC DISORDERS | 2017 |
|
RU2740913C2 |
| METHODS FOR MODULATING INTESTINAL MICROBIOTA | 2017 |
|
RU2738265C2 |
| COMBINATION THERAPY OF PULMONARY HYPERTENSION | 2016 |
|
RU2780758C2 |
| CRYSTALLINE STRUCTURE OF PHOSPHODIESTERASE 5 AND ITS USING | 2002 |
|
RU2301259C2 |
| NOVEL RAPIDLY ACTING PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS ELICITING ACTIVITY IN SEXUAL DYSFUNCTION AND CACAO POWDER AND THEIR USING | 2003 |
|
RU2312665C2 |
| METHOD OF TREATING HEPATIC FIBROSES | 2017 |
|
RU2740902C2 |
| COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | 2011 |
|
RU2745439C2 |
| COMPOSITIONS AND METHODS FOR IMPROVING OR MAINTAINING MUSCLE PERFORMANCE | 2011 |
|
RU2606763C2 |
| METHOD OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) WITH USING CYSTEAMINE PRODUCTS | 2008 |
|
RU2498795C2 |
